Atossa Therapeutics Inc. [NASDAQ: ATOS] loss -10.16% or -0.44 points to close at $3.89 with a heavy trading volume of 37936855 shares. The company report on February 3, 2021 that Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen.
Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announces updated findings following 26 months of Expanded Access (or “compassionate use”) single-patient studies of Atossa’s Endoxifen.
“To date, the patient has not had a recurrence of breast cancer, as assessed by clinical breast examination and mammography; has not had treatment-related changes in periodic laboratory blood tests and general clinical examinations; and, the treatment has been well tolerated, including an absence of typical vasomotor symptoms commonly associated with tamoxifen (for example, night sweats and hot flashes), an FDA-approved drug frequently prescribed for breast cancer treatment,” commented Sidney Goldblatt, M.D., Principal Investigator.
It opened the trading session at $4.01, the shares rose to $4.10 and dropped to $3.50, the range by which the price of stock traded the whole day. The daily chart for ATOS points out that the company has recorded 0.78% gains over the past six months. However, it is still -418.67% lower than its most recent low trading price.
If we look at the average trading volume of 18.59M shares, ATOS reached to a volume of 37936855 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Atossa Therapeutics Inc. [ATOS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ATOS shares is $6.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ATOS stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Atossa Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 26, 2018.
The Average True Range (ATR) for Atossa Therapeutics Inc. is set at 0.51 The Price to Book ratio for the last quarter was 4.27, with the Price to Cash per share for the same quarter was set at 0.13.
Trading performance analysis for ATOS stock
Atossa Therapeutics Inc. [ATOS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 76.02. With this latest performance, ATOS shares gained by 322.50% in over the last four-week period, additionally plugging by 0.78% over the last 6 months – not to mention a rise of 159.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATOS stock in for the last two-week period is set at 72.91, with the RSI for the last a single of trading hit 73.67, and the three-weeks RSI is set at 71.32 for Atossa Therapeutics Inc. [ATOS]. The present Moving Average for the last 50 days of trading for this stock 1.52, while it was recorded at 3.33 for the last single week of trading, and 2.37 for the last 200 days.
Atossa Therapeutics Inc. [ATOS]: A deeper dive into fundamental analysis
Return on Total Capital for ATOS is now -156.88, given the latest momentum, and Return on Invested Capital for the company is -156.92. Return on Equity for this stock declined to -157.00, with Return on Assets sitting at -131.50. When it comes to the capital structure of this company, Atossa Therapeutics Inc. [ATOS] has a Total Debt to Total Equity ratio set at 0.38. Additionally, ATOS Total Debt to Total Capital is recorded at 0.38, with Total Debt to Total Assets ending up at 0.35. Long-Term Debt to Equity for the company is recorded at 0.09, with the Long-Term Debt to Total Capital now at 0.08.
Reflecting on the efficiency of the workforce at the company, Atossa Therapeutics Inc. [ATOS] managed to generate an average of -$2,873,296 per employee.Atossa Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.20 and a Current Ratio set at 7.20.
Atossa Therapeutics Inc. [ATOS]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Atossa Therapeutics Inc. posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.33/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 21.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ATOS.
An analysis of insider ownership at Atossa Therapeutics Inc. [ATOS]
There are presently around $3 million, or 4.20% of ATOS stock, in the hands of institutional investors. The top three institutional holders of ATOS stocks are: VANGUARD GROUP INC with ownership of 208,896, which is approximately 73.086% of the company’s market cap and around 0.12% of the total institutional ownership; MORGAN STANLEY, holding 131,557 shares of the stock with an approximate value of $0.51 million in ATOS stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $0.35 million in ATOS stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Atossa Therapeutics Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 18 institutional holders increased their position in Atossa Therapeutics Inc. [NASDAQ:ATOS] by around 445,487 shares. Additionally, 3 investors decreased positions by around 20,949 shares, while 4 investors held positions by with 256,231 shares. The mentioned changes placed institutional holdings at 722,667 shares, according to the latest SEC report filing. ATOS stock had 13 new institutional investments in for a total of 223,276 shares, while 0 institutional investors sold positions of 0 shares during the same period.